osteoarthritis

Red stop sign on road
Biotech

Eli Lilly sidelines pain prospect in another pipeline shift

The asset was originally licensed from Asahi Kasei Pharma in 2021, and Lilly is now exploring other possible indications for the P2X7 inhibitor.
Darren Incorvaia Oct 30, 2025 2:19pm
Broom sweep clean

Novartis axes osteoarthritis asset and radioligand therapy

Apr 29, 2025 5:24am
X ray illustration of a running person with pain in knee joint with blue background

Novartis culls ph. 2 knee pain trial testing anti-ADAMTS-5 asset

Apr 16, 2025 2:55pm
In Laboratory Over the Shoulder View of Scientist in Protective Clothes Doing Research on a Personal Computer

GSK pays AI biotech $45M upfront to identify fibrotic targets

Dec 10, 2024 4:59am
knee x-ray

Levicept's ex-Pfizer drug reduces osteoarthritis pain in ph. 2

Aug 6, 2024 1:00am
closed shuttered shut down closed

Ampio prepares to wind down after final therapeutic dream dies

Mar 26, 2024 9:01am